Today’s top U.S. stocks: Lufax Holding Ltd ADR (LU ↑4.8%), Curevac N.V. (CVAC ↑4.9%)
The best performing companies today were Lufax Holding Ltd ADR (LU, up 4.8%) and Curevac N.V. (CVAC, up 4.9%).
As a whole the market struggled, though both the Nasdaq and NYSE composites were down less than 1%.
Top movers in U.S. markets Tuesday, August 17, 2021
Lufax Holding Ltd ADR (LU) was the largest gainer today.
Shares in the company rose 4.8% to $8.33.Learn more about investing in Lufax Holding Ltd ADR in Finder’s full guide.
Another strong performer was Curevac N.V. (CVAC), the NASDAQ company.
It rose 4.9% to reach $64.30.
Find a new online broker
Check out fees and features in our comparison table to find a better deal today.
| Stock | Price | % change |
|---|---|---|
| Lufax Holding Ltd ADR (LU) | $8.33 | 4.8% |
| Curevac N.V. (CVAC) | $64.30 | 4.9% |
| Ke Holdings Inc ADR (BEKE) | $18.22 | 3.1% |
| Moderna Inc. (MRNA) | $389.90 | 4.3% |
| Sea Limited ADR (SE) | $309.81 | 6.7% |
| Biontech Se ADR (BNTX) | $356.54 | 3.9% |
| Maravai Lifesciences Holdings Inc. Class A (MRVI) | $58.31 | 5.6% |
| Kroger Company (The) (KR) | $45.53 | 4.8% |
| Regeneron Pharmaceuticals Inc. (REGN) | $642.77 | 2.3% |
| Masimo Corp. (MASI) | $274.15 | 1.7% |
Market movers Tuesday 17 August 2021
Each weekday we round up the biggest gainers on the NYSE and Nasdaq, ranked by price percentage from market open to market close. To avoid higher price volatility we only include stocks with market caps of more than $10 billion. Price changes are calculated from the open to the close on the trading day, but these prices may be subject to minor variation depending on data availability.
Need a better broker? Check out Finder’s full review of the best online brokers right now.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
